NCT06850623 2026-03-04
ENACT
EXACT Therapeutics AS
Phase 2 Recruiting
Clinical Trials
13 trialsNCT07259317 2026-02-20
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Corcept Therapeutics
Phase 2 Recruiting
NCT03856658 2025-06-17
Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases
Corewell Health West
Phase 2 Active not recruiting
NCT06813079 2025-02-18
Using Tumor Models to Determine Treatments
University Health Network, Toronto
Phase 2 Not yet recruiting
NCT06573398 2024-08-27
Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC
Ruijin Hospital
Phase 2 Not yet recruiting
NCT04146441 2023-01-19
PDAC
St. Olavs Hospital
Phase 2 Completed
NCT03403101 2021-04-09
The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer
Fudan University
Phase 2 Unknown
NCT00226746 2020-09-18
Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer
New York Presbyterian Brooklyn Methodist Hospital
Phase 2 Withdrawn
NCT01839487 2020-07-20
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer
Halozyme Therapeutics
Phase 2 Completed
NCT01608711 2017-05-16
A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002
Astellas Pharma Inc
Phase 2 Completed
NCT02243007 2017-05-16
Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Terminated
NCT00902291 2015-09-14
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Astellas Pharma Inc
Phase 2 Completed
NCT01394120 2012-03-27
Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer
Grupo Hospital de Madrid
Phase 2 Unknown